ProKidney (MEX:PROK) ROCE % : -36.46% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ProKidney's annualized ROCE % for the quarter that ended in Mar. 2024 was -36.46%.

ProKidney ROCE % Historical Data

The historical data trend for ProKidney's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney ROCE % Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-240.95

-283.75

-54.80

-26.47

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial									-27.57	-27.97	-37.20	-18.08	-36.46

ProKidney ROCE % Calculation

ProKidney's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2197.13	/	( ( (10098.85 - 211.98)	+	(7138.554 - 425.001) )	/ 2 )
	=	-2197.13	/	( (9886.87	+	6713.553)	/ 2 )
	=	-2197.13	/	8300.2115
	=	-26.47 %

ProKidney's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-2338.944	/	( ( (7138.554 - 425.001)	+	(6435.414 - 320.324) )	/ 2 )
	=	-2338.944	/	( ( 6713.553	+	6115.09 )	/ 2 )
	=	-2338.944	/	6414.3215
	=	-36.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

ProKidney (MEX:PROK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ProKidney ROCE % Related Terms

Thank you for viewing the detailed overview of ProKidney's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney (MEX:PROK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PROK:USA

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.